Activities in the upcoming year
Update from EnteroTarget: We're excited to share some significant developments at EnteroTarget as we step into the new year. Expansion of Phase 1a Trial: Our ongoing Phase 1a trial of the EnteroCalm rectal solution is gaining momentum. We're expanding to include at least three clinical groups in Poland. Preclinical Investigations on the Horizon: Exciting developments are on the horizon with the EnteroCalm capsule. We're gearing up to commence preclinical investigations in pigs, expected to start in Q2 of this year. Financial Stability: We're pleased to confirm that the liquidity for these planned activities has been secured, ensuring a smooth and uninterrupted progression of our projects. Continued Collaboration with Bioton SA: On the partnership front, we're thrilled to continue our collaboration with the esteemed insulin manufacturer, Bioton SA. This partnership is a testament to our commitment to excellence and innovation in the healthcare field. Stay tuned for more updates as we continue to make strides in improving patient care through our groundbreaking work at EnteroTarget. Jørgen Olsen, CEO #InflammatoryBowelDisease #Ulcerativecolitis #Insulin #topicaltreatment #Colonicrelease #EnteroCalm #EnteroShuttle #EnteroTarget
Jeremy Launders
3mo
Great progress Jørgen Olsen, BIOTON S.A. are delighted to be involved in the exciting EnteroTarget journey.
Congratulations Jørgen! hard work pays off!